Project Grant W81XWH1810758

This Project Grant award, funded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research on using cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer (mCRPC). The $680,453 award to the University of Wisconsin System will investigate three key aims: 1) determining if baseline circulating tumor DNA (ctDNA) fragmentomics scores are prognostic biomarkers in...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) provides $627,474 to support research aimed at improving the detection, diagnosis, and understanding of prostate cancer progression. The key objectives of this 5-year project are to: 1) Identify clinically relevant epigenomic signatures in liquid biopsies that can detect the emergence of treatment-resistant neuroendocrine...

The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...

The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...

This Project Grant award of $244,228 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports a research project at the University of Texas MD Anderson Cancer Center. The project aims to develop a functional proteomics approach to accurately map patient tumor samples to preclinical lung cancer models. Specifically, the researchers will: Expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using a reverse-phase protein...